Results 51 to 60 of about 1,262,540 (308)

Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer

Annals of Oncology, 2013
Polychemotherapy and biological drugs have increased therapeutic options and outcomes of advanced colorectal cancer (CRC). We examined the relation between progression-free survival (PFS), post-progression survival (PPS) and overall survival (OS) in trials of modern (oxaliplatin- and irinotecan-based) chemotherapy alone or with targeted therapies for ...
F, Petrelli, S, Barni
openaire   +2 more sources

Optimal duration of a first-line palliative chemotherapy in disseminated colorectal cancer – a review of the literature from a developing country perspective

Contemporary Oncology, 2016
We still do not know whether the presently used protocol of the first-line palliative treatment of disseminated colorectal cancer (FOLFOX/FOLFIRI protocol) allows maximization of therapeutic response and minimization of side effects.
Wojciech Rogowski, Violetta Sulżyc-Bielicka   +1 more
doaj   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

Acta Oncologica
Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of
Aino Rajamaki, Marc Sorigue, Roosa E.I. Prusila, Milla E.L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen   +10 more
doaj   +1 more source

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

Exploring the effects of doxorubicin on survival rates in glioma patients: a comprehensive systematic review

European Journal of Medical Research
Background Glioma is still one of the most aggressive and common types of brain and central nervous system cancer, with few effective treatment options.
Elyar Mahboubi, Mahdieh Mondanizadeh, Amir Almasi-Hashiani, Elham Ghasemi   +3 more
doaj   +1 more source

MRI radiomics predicts progression-free survival in prostate cancer

Frontiers in Oncology, 2022
ObjectiveTo assess the predictive value of magnetic resonance imaging (MRI) radiomics for progression-free survival (PFS) in patients with prostate cancer (PCa).Methods191 patients with prostate cancer confirmed by puncture biopsy or surgical pathology were included in this retrospective study, including 133 in the training group and 58 in the ...
Yushan Jia, Shuai Quan, Jialiang Ren, Hui Wu, Aishi Liu, Yang Gao, Fene Hao, Zhenxing Yang, Tong Zhang, He Hu   +9 more
openaire   +3 more sources

Survival Outcomes and Complications Among Canadian Children With Retinoblastoma: A Population‐Based Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Retinoblastoma (RB) is the most common pediatric ocular cancer, yet population‐based data on survival and risk factors remain limited. This study aimed to describe survival in a large national RB cohort and identify predictors of death and complications.
Samuel Sassine, Ofélie Trudeau‐Ferrin, Caroline Laverdière, Patrick Hamel, Rosanne Superstein, Bénédicte Koukoui, Carole Provost, Paul C. Nathan, Vijay Ramaswamy, Furqan Shaikh, Brenda Gallie, Ashwin Mallipatna, Stephanie Kletke, Helen Dimaras, Hallie Coltin   +14 more
wiley   +1 more source

Impact of diagnosis to treatment interval on outcomes in patients with newly diagnosed marginal zone lymphoma - a US multisite study

Experimental Hematology & Oncology
Diagnosis-to-treatment interval (DTI) is an important prognostic factor in patients with newly diagnosed aggressive lymphomas, however the impact of DTI on outcomes in marginal zone lymphoma (MZL) is unknown.
Narendranath Epperla, Geoffrey Shouse, Natalie S. Grover, Pallawi Torka, Kaitlin Annunzio, Marcus Watkins, Andrea Anampa-Guzmán, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Reem Karmali, Nancy L. Bartlett, Adam J. Olszewski   +13 more
doaj   +1 more source

Whole brain radiation therapy alone versus radiosurgery for patients with 1–10 brain metastases from small cell lung cancer (ENCEPHALON Trial): study protocol for a randomized controlled trial [PDF]

, 2018
Background: Conventional whole brain radiotherapy (WBRT) has been established as the treatment standard in patients with cerebral metastases from small-cell lung cancer (SCLC), however, it has only modest efficacy and limited prospective data is ...
Bernhardt, Denise, Debus, Jürgen, El Shafie, Rami, Heußel, Claus Peter, Hommertgen, Adriane, Hörber-Rieber, Juliane, Kappes, Jutta, Kieser, Meinhard, Klose, Christina, Krisam, Johannes, König, Laila, Mair-Walther, Johanna, Paul, Angela, Rieken, Stefan, Schmitt, Daniela, Steins, Martin, Thomas, Michael, Welzel, Thomas   +17 more
core   +1 more source